EASL Studio Podcast: Rifaximin for Hepatic Encephalopathy: Balancacing Benefits and Risks in the Era of Antimicrobial Resistance

For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance.Moderator: Debbie ShawcrossSpeakers: Rajiv Jalan, Vishal Patel, Jonel TrebickaAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.This EASL Studio is supported by Alfasigma and Norgine. EASL has received no input from Alfasigma or Norgine with regards to the content of this programme.